Daily non-political popular news in brief.

Study shows zinc doesn't help head and neck cancer patients

Zinc sulfate, a supplement thought to be helpful in regaining the sense of taste for some head and neck cancer patients after radiation therapy, has been found to have no significant impact on preventing or curing taste alteration, according to a study released today in the International Journal for Radiation Oncology, Biology, Physics, the official journal of ASTRO.

Read more »

Keywords: study, shows, zinc, doesn, head, neck, cancer, patients, show, patient

« Previous | Next »

Similar news on "Study shows zinc doesn't help head and neck cancer patients":

1. Cetuximab may prolong survival for head and neck cancer patients
   01-18-2007 · EurekAlert!
   Preliminary findings show adding the chemotherapy drug cetuximab (brand name Erbitux) to radiation therapy and chemotherapy may help some patients with head and neck cancer live longer, according to a study presented at the plenary session of the Multidisciplinary Head and Neck Cancer Symposium, co-sponsored by the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Head and Neck Society.
   Similar news · Read more »
   
2. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
   06-02-2007 · EurekAlert!
   The study showed that sipuleucel-T did not significantly delay the time it took for a patient's PSA to reach a value of 3 ng/ml, the primary endpoint of the study, but it did show a prolongation in prostate-specific antigen doubling time (PSADT).
   Similar news · Read more »
   
3. Intravenous chemoradiation effective for inoperable head, neck cancer; easier for patients, doctors
   11-06-2006 · EurekAlert!
   Chemoradiation (radiation and chemotherapy given at the same time) given through a needle or tube inserted into a vein (intravenous) is as effective as treatment given directly to the tumor through a tube inserted into an artery (intra-arterial) for patients with inoperable head and neck cancer, according to a randomized study presented at the plenary session November 6, 2006, at the American Society for Therapeutic Radiology and Oncology's 48th Annual Meeting in Philadelphia.
   Similar news · Read more »
   
4. Decrease in the use of radiotherapy procedures for the treatment of cancer in hospitals
   10-09-2007 · EurekAlert!
   The study is based on data of patients, treated in any of the 10 Andalusian public hospitals for one year, who were submitted to radiotherapy procedures for the treatment of tumours in the breast, lung, head and neck, cervix and endometrium.
   Similar news · Read more »
   
5. Study identifies patients' reasons for quitting jobs after treatment for head and neck cancer
   05-21-2007 · EurekAlert!
   After treatment, 38.1 percent of patients with head and neck cancer who were employed at the time of cancer diagnosis reported discontinuing work because of their cancer and treatment, according to a report in the May issue of Archives of Otolaryngology-Head & Neck Surgery, one of the JAMA/Archives journals.
   Similar news · Read more »
   
6. Research shows survival benefit for leukemia patients treated with arsenic trioxide
   06-04-2007 · EurekAlert!
   Through participation in a government-sponsored multi-year study, researchers at the Comprehensive Cancer Center at Wake Forest University have helped confirm that arsenic trioxide -- marketed as Trisenox -- significantly improves patient survival when coupled with standard chemotherapy treatment in newly diagnosed patients with acute promyelocytic leukemia, or APL.
   Similar news · Read more »
   
7. Penn's Abramson Cancer Center part of major phase III study for myeloma
   11-21-2007 · EurekAlert!
   Researchers from the UPenn's Abramson Cancer Center announced today that findings from two international clinical trials show unprecedented survival for patients with myeloma, a cancer the blood-making cells of bone marrow. Findings show that with the oral drug lenalidomide, in combination with dexamethasone, patients significantly improved by all measures where previous treatments had failed -- including a median survival of nearly three years -- the longest median survival known for this difficult to treat patient group.
   Similar news · Read more »
   
8. Study examines factors associated with survival in advanced laryngeal cancer
   12-17-2007 · EurekAlert!
   Type of treatment, sex, race and insurance status are associated with survival rates among patients with advanced laryngeal cancer, according to a report in the December issue of Archives of Otolaryngology -- Head & Neck Surgery, one of the JAMA/Archives journals.
   Similar news · Read more »
   
9. Cetuximab with radiotherapy does not increase side effects for head and neck cancer patients
   01-18-2007 · EurekAlert!
   The addition of Cetuximab (brand name Erbitux) to radiation therapy treatments does not increase the rate or duration of some side effects in the treatment of advanced head and neck cancers, according to a study presented at the plenary session today at the Multidisciplinary Head and Neck Cancer Symposium, co-sponsored by the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Head and Neck Society.
   Similar news · Read more »
   
10. Support groups don't extend survival of metastatic breast cancer patients, Stanford study finds
    07-23-2007 · EurekAlert!
    A new study from a team of Stanford University School of Medicine researchers led by David Spiegel, MD, shows that participating in support groups doesn't extend the lives of women with metastatic breast cancer. The results differ from oft-cited previous findings by Spiegel, that showed group psychotherapy extended survival time.
    Similar news · Read more »